MedWatch

Novo plant manager: Kalundborg-plant to produce next generation diabetes drugs

A DKK 650 million-investment is to prepare Novo Nordisk's production plant in Kalundborg, Denmark, for manufacturing next generation diabetes products. "We improve the flexibility of our production setup," says Novo's head of Diabetes API production.

Foto: Novo Nordisk/PR

The diabetes therapy of the future is to be produced in Novo Nordisk's manufacturing site in Kalundborg, Denmark. The Danish drug group has therefore put DKK 650 million (USD 97.82 million) into upgrading, expanding and rebuilding the plant.

"With the investments, we reconstruct the two factories in question so that they can produce more than one product. That way, the plants will not just continue to produce already marketed products but also the next generation of diabetes drugs," says Michael Hallgren, head of Diabetes API production in Novo Nordisk.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier